$ANKM
Ankam, Inc.

2024 Q1 Form 10-K Financial Statement

#000178162924000005 Filed on February 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $9.760K $7.480K $27.17K
YoY Change 214.94% 1443.92%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $47.42K -$93.28K $121.1K
YoY Change 176.31%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $36.16K $24.94K $24.94K
YoY Change 418.2% 88.23%
% of Gross Profit
Operating Expenses $128.5K -$89.27K $325.2K
YoY Change 51.54% 470.05%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $44.90K -$179.2K $179.2K
YoY Change 0.0% 1222.24%
Pretax Income -$118.7K -$63.60K $279.2K
YoY Change -245.34% 404.89%
Income Tax
% Of Pretax Income
Net Earnings -$118.7K -$63.60K -$279.2K
YoY Change 45.34% 404.89%
Net Earnings / Revenue -1216.32% -850.27% -1027.33%
Basic Earnings Per Share -$0.03 -$0.06
Diluted Earnings Per Share -$0.03 -$0.01 -$0.06
COMMON SHARES
Basic Shares Outstanding 4.328M shares 4.328M shares 4.328M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $710.00 $290.00 $290.00
YoY Change -87.28%
Cash & Equivalents $707.00 $286.00
Short-Term Investments
Other Short-Term Assets $72.28K $64.49K $64.49K
YoY Change -62.01%
Inventory
Prepaid Expenses $36.01K $15.85K
Receivables $0.00 $21.39K $21.39K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $72.99K $86.17K $86.17K
YoY Change -42.23% -51.27% -51.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $144.0K $22.16K $22.15K
YoY Change -45.07% -91.77% -91.77%
TOTAL ASSETS
Total Short-Term Assets $72.99K $86.17K $86.17K
Total Long-Term Assets $144.0K $22.16K $22.15K
Total Assets $217.0K $108.3K $108.3K
YoY Change -44.15% -75.71% -75.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $244.0K $84.00K $84.00K
YoY Change -31.98%
Accrued Expenses $23.53K $44.90K $44.90K
YoY Change -70.0%
Deferred Revenue
YoY Change
Short-Term Debt $365.6K $292.0K $292.0K
YoY Change 35.82%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $661.0K $433.6K $433.6K
YoY Change 28.01% -11.9% -11.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $661.0K $433.6K $433.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $661.0K $433.6K $433.6K
YoY Change 28.01% -11.9% -11.9%
SHAREHOLDERS EQUITY
Retained Earnings -$479.6K -$360.9K
YoY Change -393.49% -541.53%
Common Stock $4.328K $4.328K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$444.0K -$325.3K -$325.3K
YoY Change
Total Liabilities & Shareholders Equity $217.0K $108.3K $108.3K
YoY Change -44.15% -75.71% -75.71%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$118.7K -$63.60K -$279.2K
YoY Change 45.34% 404.89%
Depreciation, Depletion And Amortization $36.16K $24.94K $24.94K
YoY Change 418.2% 88.23%
Cash From Operating Activities $84.85K -$320.4K $320.4K
YoY Change -0.76% 137.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions -$158.0K
YoY Change
Other Investing Activities -$158.0K $241.4K $241.4K
YoY Change
Cash From Investing Activities -$158.0K $241.4K -$241.4K
YoY Change 213.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $73.61K 77.01K $77.01K
YoY Change -13.09% -63.89%
NET CHANGE
Cash From Operating Activities $84.85K -320.4K $320.4K
Cash From Investing Activities -$158.0K 241.4K -$241.4K
Cash From Financing Activities $73.61K 77.01K $77.01K
Net Change In Cash $421.00 -1.990K $1.991K
YoY Change -152.56% 42.21%
FREE CASH FLOW
Cash From Operating Activities $84.85K -$320.4K $320.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001781629
CY2023Q4 us-gaap Development In Process
DevelopmentInProcess
usd
CY2022 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
usd
CY2023 ankm Increase Decrease Project Process
IncreaseDecreaseProjectProcess
usd
CY2023 us-gaap Capitalized Computer Software Period Increase Decrease
CapitalizedComputerSoftwarePeriodIncreaseDecrease
usd
CY2022 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023 us-gaap Interest Paid
InterestPaid
usd
CY2022 us-gaap Interest Paid
InterestPaid
usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
usd
CY2022 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-11-30
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
333-255392
CY2023 dei Entity Registrant Name
EntityRegistrantName
ANKAM, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
61-1900749
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
5348 Vegas Drive
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89108
CY2023 dei City Area Code
CityAreaCode
1361
CY2023 dei Local Phone Number
LocalPhoneNumber
2325001
CY2023 dei Contact Personnel Email Address
ContactPersonnelEmailAddress
[email protected]
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Public Float
EntityPublicFloat
0 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4327996 shares
CY2023 dei Auditor Firm
AuditorFirmId
3289
CY2023 dei Auditor Name
AuditorName
Accell Audit & Compliance
CY2023 dei Auditor Location
AuditorLocation
Tampa, Florida
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
286 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2277 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21390 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4800 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15847 usd
CY2023Q4 us-gaap Assets Net
AssetsNet
48643 usd
CY2022Q4 us-gaap Assets Net
AssetsNet
169752 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
86166 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
176829 usd
CY2022Q4 us-gaap Development In Process
DevelopmentInProcess
198710 usd
CY2023Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
22157 usd
CY2022Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
70491 usd
CY2023Q4 us-gaap Assets
Assets
108323 usd
CY2022Q4 us-gaap Assets
Assets
446030 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
84000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
123499 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
12700 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
4000 usd
CY2023Q4 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
292026 usd
CY2022Q4 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
215017 usd
CY2023Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
44900 usd
CY2022Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
149660 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
433626 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
492176 usd
CY2023Q4 us-gaap Liabilities
Liabilities
433626 usd
CY2022Q4 us-gaap Liabilities
Liabilities
492176 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4327996 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4327996 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4327996 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4327996 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4328 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4328 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31262 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31262 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-360893 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81736 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-325303 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-46146 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108323 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
446030 usd
CY2023 us-gaap Revenues
Revenues
27173 usd
CY2022 us-gaap Revenues
Revenues
1760 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
390 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1051 usd
CY2023 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
72000 usd
CY2022 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
12000 usd
CY2023 us-gaap Professional Fees
ProfessionalFees
48656 usd
CY2022 us-gaap Professional Fees
ProfessionalFees
17200 usd
CY2023 us-gaap Other Expenses
OtherExpenses
179230 usd
CY2022 us-gaap Other Expenses
OtherExpenses
13555 usd
CY2023 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
24944 usd
CY2022 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
13245 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
325220 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
57051 usd
CY2023 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
298047 usd
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
55291 usd
CY2023 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
18890 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
279157 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
55291 usd
CY2023 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
-279157 usd
CY2022 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
-55291 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4327996 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4085776 shares
CY2021Q4 us-gaap Shares Issued
SharesIssued
3250000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-23195 usd
CY2022 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1077996 usd
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
32340 shares
us-gaap Net Income Loss
NetIncomeLoss
-55291 usd
CY2022Q4 us-gaap Shares Issued
SharesIssued
4327996 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-46146 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-279157 usd
CY2023Q4 us-gaap Shares Issued
SharesIssued
4327996 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-325303 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-279157 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-55291 usd
CY2023 us-gaap Amortization And Depreciation Of Decontaminating And Decommissioning Assets
AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets
24944 usd
CY2022 us-gaap Amortization And Depreciation Of Decontaminating And Decommissioning Assets
AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets
13245 usd
CY2023 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
18890 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16590 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4800 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-15847 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3265 usd
CY2023 ankm Increase Decrease In Right Of Use Assets And Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLiabilitiesNet
-15949 usd
CY2022 ankm Increase Decrease In Right Of Use Assets And Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLiabilitiesNet
20093 usd
CY2022 ankm Increase Decrease Project Process
IncreaseDecreaseProjectProcess
198710 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
39499 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-123499 usd
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
8700 usd
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
320390 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
134885 usd
CY2022 us-gaap Capitalized Computer Software Period Increase Decrease
CapitalizedComputerSoftwarePeriodIncreaseDecrease
77000 usd
CY2023 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
241390 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-241390 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
77000 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32340 usd
CY2023 us-gaap Loans And Leases Receivable Related Parties Period Increase Decrease
LoansAndLeasesReceivableRelatedPartiesPeriodIncreaseDecrease
77009 usd
CY2022 us-gaap Loans And Leases Receivable Related Parties Period Increase Decrease
LoansAndLeasesReceivableRelatedPartiesPeriodIncreaseDecrease
180945 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77009 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
213285 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1991 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1400 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2277 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
877 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
286 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2277 usd
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
51052 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
179592 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_842_eus-gaap--UseOfEstimates_zhjPfzGYHVt1" style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86B_zXDmnYMIdyZ3">Use of Estimates</span></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2023Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
51052 usd
CY2023Q4 us-gaap Debt Current
DebtCurrent
292026 usd
CY2022Q4 us-gaap Debt Current
DebtCurrent
215017 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
360893 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
81736 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
360893 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
81736 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
75787 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
17165 usd
CY2023Q4 ankm Less
Less
-75787 usd
CY2022Q4 ankm Less
Less
-17165 usd

Files In Submission

Name View Source Status
ankm-20231130_lab.xml Edgar Link unprocessable
0001781629-24-000005-index-headers.html Edgar Link pending
0001781629-24-000005-index.html Edgar Link pending
0001781629-24-000005.txt Edgar Link pending
0001781629-24-000005-xbrl.zip Edgar Link pending
ankm-20231130.xsd Edgar Link pending
ankm_10k2023.htm Edgar Link pending
exh31.htm Edgar Link pending
exh32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ankm-20231130_def.xml Edgar Link unprocessable
ankm-20231130_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ankm_10k2023_htm.xml Edgar Link completed
ankm-20231130_cal.xml Edgar Link unprocessable